Inactivated COVID-19 vaccines to make a global impact
- PMID: 33548196
- PMCID: PMC7906657
- DOI: 10.1016/S1473-3099(21)00020-7
Inactivated COVID-19 vaccines to make a global impact
Comment on
-
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.Lancet Infect Dis. 2021 Jun;21(6):803-812. doi: 10.1016/S1473-3099(20)30987-7. Epub 2021 Feb 3. Lancet Infect Dis. 2021. PMID: 33548194 Free PMC article. Clinical Trial.
References
-
- WHO Draft landscape of COVID-19 candidate vaccines. Jan 15, 2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-cand...
-
- US Centers for Disease Control and Prevention COVID-19—older adults. Dec 13, 2020. http://cdc.gov/coronavirus/2019-ncov/need-extra-precautions/older-adults...
-
- Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(20)30987-7. published online Feb 3. - DOI - PMC - PubMed
-
- Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020 doi: 10.1016/S1473-3099(20)30843-4. published online Nov 17. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
